As I See It

As I See It: Access to data

As I See It: Access to data

We need for pharmaceutical companies to come forward and make the pledge to stop hiding data

As I See It: FDA and the First Amendment

As I See It: FDA and the First Amendment

FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals

As I See It: Small is the new Big

As I See It: Small is the new Big

It's fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes

As I See It: Quality programs

As I See It: Quality programs

Keeping up with quality programs often feels like a safari in a jungle of government paperwork

As I See It: FDA reorganization

As I See It: FDA reorganization

Could PAG change the FDA inspection paradigm from honest, objective assessments to faster, easier ones?

As I See It: Transparency and clinical trial data

As I See It: Transparency and clinical trial data

By opposing making clinical trial data public, Pharma is once again swimming against the current

As I See It: The Sunshine Act's CME exclusion

As I See It: The Sunshine Act's CME exclusion

CMS recognized that the rules in place for CME provide for separation from supporter influence

As I See It: Dealing with the Surveillance State

As I See It: Dealing with the Surveillance State

Just like the NSA can monitor national security, FDA market-watchers can track what pharma marketers are doing.

As I See It: The battle for better compliance

As I See It: The battle for better compliance

While there are successes in the battle for better adherence/compliance, we're losing the war

As I See It: Activism and the FDA

As I See It: Activism and the FDA

Appendages of the HHS secretary's apron strings, FDA commissioners must toe the "party line"

Email Newsletters